Skip to content
Talphera, Inc. logo

Talphera, Inc.

TLPH

Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for use in medically supervised settings, particularly hospitals and intensive care units.

Market cap
$70.58M+574%
Revenue$1.0K-96.3%
Net income-$14.3M-22.4%
Trailing twelve months · change vs. prior year

Earnings

Next report

Aug 13, 2026 (in a month)
EPS estimate-$0.07

Financials

Q1 2026

Income statement

See full
Revenue--100%
Operating income-$3.9M-35.4%
Net income-$2.6M+1.4%

Balance sheet

See full
Cash & equivalents$3.8M-29.0%
Total equity$18.5M+230%
Total assets$30.2M+101%

Cash flow

See full
Operating cash flow-$3.4M+2.0%

Valuation & ratios

Valuation

See full
Market cap$70.58M+574%
P/S70,583.5×+70,232×

Profitability

See full
Operating margin-1,451,600%-1,507,145pp
Net margin-1,425,300%-1,471,200pp

Returns & leverage

See full
Return on equity-118.4%+15.4pp
Current ratio5.3×+2.2×

Competitors

Profile

Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for use in medically supervised settings, particularly hospitals and intensive care units. The company's primary value proposition centers on its lead product candidate, Niyad, which is designed to provide regional anticoagulation for patients undergoing continuous renal replacement therapy. Talphera aims to address unmet needs in acute care by offering alternatives to systemic anticoagulants that carry high bleeding risks.

Competitive position

Talphera is a clinical-stage developer seeking to establish a first-mover advantage with the first FDA-approved regional anticoagulant for CRRT. It competes by targeting a significant portion of the market that currently uses no anticoagulation due to safety concerns with existing systemic options.

GeographiesUnited States
Customer segmentsHospitals, Government Agencies, Specialty Clinics
Business modelR&D, Licensing, B2B
SuppliersContract Manufacturing Organizations (CMOs), Active Pharmaceutical Ingredient (API) suppliers, Clinical Research Organizations (CROs)
CustomersHospitals, Department of Defense, Dialysis centers, Specialty distributors
Listed2011
Employees15.0
CEOVincent J. Angotti
FilingsSEC EDGAR

Questions, answered.

What is Talphera, Inc.'s market cap?
Talphera, Inc. (TLPH) has a market capitalization of $70.6M and trades on NASDAQ.
What is Talphera, Inc.'s revenue and profitability?
Talphera, Inc. generated $1.0K in trailing twelve-month revenue with a net loss of $14.3M, representing a net margin of -1425300.0%. Gross margin stands at -127.7%. These figures are based on the Q1 2026 filing.
Who are Talphera, Inc.'s competitors?
Talphera, Inc.'s key competitors include Baxter International Inc., Fresenius Medical Care, Amphastar Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.
Who does Talphera, Inc. partner with?
Talphera, Inc.'s notable partners include Alora Pharmaceuticals, LLC, XOMA (US) LLC, Laboratoire Aguettant.
What subsidiaries does Talphera, Inc. have?
Talphera, Inc.'s subsidiaries include Lowell Therapeutics, Inc..
Where is Talphera, Inc. headquartered?
Talphera, Inc. is headquartered in United States of America and employs approximately 15 people. It has been publicly traded since 2011.